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Background
Control and elimination strategies for
trachoma, lymphatic filariasis, onchocer-
ciasis, schistosomiasis, ascariasis, trichuri-
asis and hookworm infection have striking
similarities, including the use of perio-
dic mass drug administration (MDA).
Because these diseases tend to be co-
endemic in the poorest communities of
the poorest countries, such that multiple
NTDs are frequently found not just in the
same populations but within the same
individuals [1], it has been suggested that
mapping, treatment, impact monitoring,
and post-elimination surveillance could be
coordinated to better utilise limited hu-
man and financial resources. Although
many programmes now distribute multi-
ple anthelmintics simultaneously, progress
in integrating mapping [2,3,4], monitor-
ing, and surveillance [5] activities has
been slow [6]. Ideally, population sam-
pling strategies, fieldwork protocols, and
sample types (e.g., blood or urine) could
all be harmonised between diseases to
increase population compliance, simplify
overall survey procedures, and decrease
costs.
For each of these diseases, current diag-
nostic tools are imperfect (Table S1A),
especially for areas with low prevalence. A
cost-effective strategy for improved tool
development would incorporate integra-
tion of diagnostic strategies from the outset
[7,8].
To review available methods for popu-
lation-based assessment of NTDs, develop
target product profiles for tools to monitor
infection burden, and consider how those
tools would be used in the context of
disease elimination programmes, the
London School of Hygiene & Tropical
Medicine (LSHTM), in collaboration with
the World Health Organization, held a
consultation at LSHTM from July 19–20,
2010. Participants included disease ex-
perts, laboratory and field scientists,
authorities on diagnostics, control progra-
mme managers, mathematical modellers,
and health economists. By bringing to-
gether, for the first time, individuals with
such a broad spectrum of intersecting
disease- and discipline-specific interests
to consider issues surrounding integration
of diagnostic systems, the consultation
aimed to improve on the usual vertical
approach to tropical diseases research,
encouraging formulation of an innovative
approach.
This article summarises that consulta-
tion’s outcomes, suggests target product
profiles and a list of immediate research
priorities, and drafts a road map for future
efforts. We argue for development of a
multiplex platform for NTD mapping,
monitoring, and surveillance, and suggest
changes to policy that might ensue if such
a system were to become available.
Evolution of Diagnostic Needs
with Successful Programme
Implementation
We conceptualise four time points or
periods at which disease elimination pro-
grammes require diagnostics:
1. Mapping to establish baseline disease
prevalence, facilitating targeting of
interventions.
2. Impact monitoring after interventions
have commenced.
3. The stopping decision, which determines
whether the pre-defined elimination
target has been reached, allowing
discontinuation of interventions.
4. Post-elimination surveillance after interven-
tion has ceased.
Mapping and impact monitoring may
require both qualitative and quantitative
data from each individual sampled, in
order to generate information about the
prevalence and intensity of infection. As
the prevalence falls with successful control
interventions, the intensity of infection also
Citation: Solomon AW, Engels D, Bailey RL, Blake IM, Brooker S, et al. (2012) A Diagnostics Platform for the
Integrated Mapping, Monitoring, and Surveillance of Neglected Tropical Diseases: Rationale and Target Product
Profiles. PLoS Negl Trop Dis 6(7): e1746. doi:10.1371/journal.pntd.0001746
Editor: James S. McCarthy, Queensland Institute for Medical Research, Australia
Published July 31, 2012
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted,
modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under
the Creative Commons CC0 public domain dedication.
Funding: The consultation that laid the foundation for this manuscript was supported by the World Health
Organization. The funder had no role in the decision to publish, or in preparation of the manuscript, other than
the individual contributions recognised by authorship of the paper.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: anthony.solomon@lshtm.ac.uk
www.plosntds.org 1 July 2012 | Volume 6 | Issue 7 | e1746
falls. Therefore, to detect the last remain-
ing infections, a more sensitive test may
be required. However, for some NTDs
(e.g., trachoma), individuals with a low
pathogen load are unlikely to transmit
infection, so sensitivity is less important.
Specificity becomes more important as
disease prevalence decreases and is an
absolute requirement in certifying elimi-
nation [5].
To enable meaningful interpretation of
the effect of interventions, the sensitivity
and specificity of diagnostic tools used in
mapping should be about the same as the
sensitivity and specificity of tools used in
impact monitoring. One rational differ-
ence between mapping and impact mon-
itoring may be the commissioning (in
environments where high baseline infec-
tion prevalence is expected) of mapping
surveys enrolling the same number of
clusters over a larger area, in order to
save resources. For example, province- or
region-level baseline assessments of tra-
choma prevalence are now accepted for
the purposes of requesting donated azith-
romycin in areas where active trachoma
prevalence in 1–9-year-olds is expected
(and then proven) to be higher than 10%;
subsequent impact monitoring is per-
formed at district level.
Ideally, stopping decisions would be
based on documentation of the absence
of transmission. In practice, however,
these decisions are often made once there
is documentation of absence of current or
previous infection in a sentinel population,
such as children born after the time
transmission is believed to have been
interrupted [9]. Stopping decisions require
data generated using diagnostic tools
whose specificity is at least as high as
those used for mapping, to avoid unnec-
essarily prolonging MDA. Tool sensitivity
is also crucial here to avoid premature
MDA cessation and later rebound in
infection prevalence. An assay considered
adequate for mapping when prevalence is
high may have inadequate sensitivity to
detect infection in areas with low infection
intensity.
Stopping decisions are made during the
process of impact monitoring, and also
mark the commencement of post-elimina-
tion surveillance. Data generated to in-
form stopping decisions should therefore
provide useful comparators against both
impact monitoring data and data that will
subsequently be collected as part of
surveillance activities.
In general, programmes are likely to
require antigen- or nucleic acid–detection
assays (to determine prevalence of cur-
rent infection) for mapping and impact
monitoring prior to elimination, and a
combination of assays detecting antigens
(or nucleic acid) and antibodies (to assess
prevalence of exposure in particular pop-
ulation subsets) for post-elimination sur-
veillance. For the worm infections, reli-
ance on detection of transmission stages
(eggs, microfilariae) becomes more prob-
lematic as the elimination endpoint is
approached, since (other than for ascaria-
sis) this will only identify hosts infected
with both male and female adults. Specific
detection of IgG subtypes may be useful in
some cases, particularly if applied at
population level: for example, IgG4 re-
sponses are characteristic of chronic hel-
minth infections, and titres decline follow-
ing successful therapy in lymphatic
filariasis, onchocerciasis, schistosomiasis,
and strongyloidiasis. Monitoring vector,
intermediate host, or non-human reservoir
[10] populations for the presence of
parasites may be important in confirming
elimination of infection.
Apart from performance characteristics,
it is important to consider the operational
characteristics of an assay. Large popula-
tion-based surveys may require tests that
can be batched for high throughput. Point
of care tests, which generally detect
antigen or antibody in dipstick or card
format, are relatively cheap, require little
formal operator training, and can be
performed in the community [11]. They
are of particular use when programme
personnel need to make immediate deci-
sions as to whether intervention is re-
quired. This is helpful when individual
patients are being assessed. However, for
MDA, where decisions are needed on
whether or not to treat whole communities
or districts, laboratory-based tests are
probably adequate, provided samples are
easy to collect (e.g., fingerprick) and
transport (e.g., dried blood spots).
Target Product Profiles and
Immediate Research Priorities
Target product profiles for lymphatic
filariasis, trachoma, schistosomiasis, on-
chocerciasis, and soil-transmitted hel-
minths are shown for the mapping and
impact monitoring phases in Table 1, and
for the post-elimination surveillance phase
(first four diseases only) in Table 2. The
tables consider only the needs for diag-
nostic tools in mapping, monitoring, and
surveillance of human infection because
we see these as priorities for any first-
generation integrated platform for NTD
diagnostics; we have, for the moment,
put aside programme requirements for
monitoring MDA coverage; measures of
morbidity; possible emergence of drug
resistance; prevalence of infection in vec-
tors, intermediate hosts, or reservoir ani-
mals; and force of transmission through
environmental sampling.
The target product profiles that we set
out here are aspirational. Some tests (e.g.,
antigen assay for W. bancrofti [Table 1] or
Ov16 antibody assay in previously oncho-
cerciasis-endemic areas [Table 2]) appear
close to being validated for programme
use, while for others, numerous technical
hurdles remain. For this reason, we expect
some of our target product profiles—
particularly blood- or urine-based antigen
detection tests for the soil-transmitted
helminthiases—to be controversial. How-
ever, there is presently at least one
commercially available ELISA kit to
detect IgG directed against Ascaris lumbri-
coides in human serum: it should be
possible to develop a test to detect the
antigen driving that antibody response. If
such antigens only circulate briefly in the
early part of the Ascaris life cycle, this may
actually be helpful in interpreting test
results at community level, since antigen
detection will indicate the presence of
ongoing transmission. Immediate research
priorities are shown in Table 3.
Discussion
Trachoma, lymphatic filariasis, schisto-
somiasis, onchocerciasis, and soil-transmit-
ted helminth infections are found in
overlapping populations; are controlled
through broadly similar, often comple-
mentary, strategies involving MDA; and
are mapped and monitored by sampling
individuals from the population-at-risk
using strategies that are also broadly
similar but different in detail. Programmes
for their control and elimination require
improved diagnostic tools to guide deci-
sions on the required intensity, frequency,
and duration of intervention and to
conduct surveillance for re-emergence of
infection after elimination. Similarities
between target product profiles (Tables 1
and 2) suggest the feasibility and desirabil-
ity of integration of diagnostic approaches.
In many areas in which NTDs are
highly endemic, basic health infrastructure
is sparse or non-existent, and there are few
trained personnel. Local laboratories may
not have access to refrigeration, reliable
power, or piped water; have highly
variable capacity for performing diagnos-
tic assays; and the capacity they do have is
in general insufficient to meet existing
diagnostic requirements of local clinical
services. They are therefore ill-equipped to
take on the extra burden of generating
www.plosntds.org 2 July 2012 | Volume 6 | Issue 7 | e1746
Table 2. Proposed target product profiles for diagnostic tools for selected NTDs, post-elimination surveillance.a
Characteristic Lymphatic Filariasis Trachoma Schistosomiasis Onchocerciasis
Intended use Post-elimination
incidence of infection
Post-elimination
incidence of infection
Post-elimination
incidence of infection
Post-elimination
incidence of infection
Possible target population Children born after
transmission interruption
Children born after
transmission interruption
Children born after
transmission interruption
Children born after
transmission interruption
Possible sample types Blood spot Blood spot Blood spot or urine
(avoid stool if possible)
Blood spot
Ideal diagnostic marker Antibody Antibody to a conserved
species-specific epitope
of MOMP
Antibody Ov16 antibody
Availability of ideal
diagnostic marker
Not available Libraries available In development Available, but additional
validation needed
Ideal test format High throughput
laboratory assay
High throughput
laboratory assay
High throughput
laboratory assay
High throughput
laboratory assay
Population infection
thresholds (for stopping MDA)
1% Not defined 10% of school-aged
children
1/3,000
Probable sampling strategy PBPS PBPS PBPS or school surveys
(or sentinel occupations)
PBPS
aSchistosomiasis is included in this table because several countries have programmes to eliminate this disease [18,19]. The soil-transmitted helminth infections are not
included because (as for schistosomiasis in most endemic states) the current goal is prevention of morbidity in school-aged children through periodic high-coverage
MDA.
ICT, immunochromatographic card test; LF, lymphatic filariasis; MDA, mass drug administration; MOMP, major outer membrane protein of C. trachomatis; NTDs,
neglected tropical diseases; PBPS, population-based prevalence survey.
doi:10.1371/journal.pntd.0001746.t002
Table 1. Proposed target product profiles for diagnostic tools for selected NTDs, mapping, and impact monitoring.
Characteristic Lymphatic Filariasis Trachoma Schistosomiasis Onchocerciasis
Soil-Transmitted
Helminths
Intended use Mapping, monitoring,
and stopping decision
Mapping, monitoring,
and stopping decision
Mapping, monitoring,
and stopping decision
Mapping, monitoring,
and stopping decision
Mapping and monitoring
Possible target
populationa
6–15-year-old children 1–9-year-old children
(could be adjusted)
6–15-year-old children
plus occupational
groups
6–15-year-old children 6–15-year-old children
Possible sample types Blood spot Eye swab (other: mouth
or nose swab, tears)
Blood spot or urine
(avoid stool if possible)
Blood spot Blood spot or urine
(avoid stool if possible)
Ideal diagnostic marker Parasite antigen C. trachomatis
antigen
Species-specific antigen
OR pan-genus antigen
Parasite antigen Parasite antigen
Ideal test format POC or high
throughput laboratory
assay
POC or high
throughput
laboratory assay
POC assay POC or high
throughput laboratory
assay
POC assay
Availability of ideal
diagnostic marker
Available but not right
format, low reliability,
high cost, and
temperature sensitive
Available but not
right format
Not yet available Not yet available.
IgG4 antibody may
be a reasonable proxy
Not yet available
Required performance
characteristics
95% sensitive; W.
bancrofti-specific
.50% sensitive,
99.5% specific
.50% sensitive,
99.5% specific
.50% sensitive,
99.5% specific
.50% sensitive,
99.5% specific
Comparator assay
(current reference
standard)
Night blood
micro-filaraemia
Quantitative PCR Kato-Katz (multiple slides
and multiple days)
and/or urine filtration
Skin snips to detect
micro-filariae
Kato-Katz (multiple
slides and multiple days)
Possible sampling
strategies
PBPS/LQAS, school
based, sentinel sites
PBPS/LQAS, home
based, sentinel sites
PBPS/LQAS, school
based, 50/school,
increasing with control
PBPS/LQAS PBPS/LQAS, school
based
LQAS, lot quality assurance sampling; NTDs, neglected tropical diseases; PBPS, population-based prevalence survey; PCR, polymerase chain reaction; POC, point of care.
aBased on peak infection prevalence, convenience, or both.
doi:10.1371/journal.pntd.0001746.t001
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data to feed into NTD elimination pro-
grammes without provision of additional
money, staff, training, equipment, reagents,
and utilities—or robust technologies that
could perform well despite limitations to
supply of these resources.
The ideal integrated system might there-
fore be a portable, self-contained diag-
nostics platform, capable of performing
multiplex assays for several infections of
interest on one or a small number of sample
types. A system employing microfluidics
(‘‘lab-on-a-chip’’) [12,13,14] technology
could fulfil these requirements. The plat-
form should be able to simultaneously
undertake multiple roles in different NTD
control programmes, each of which might
be at various points of evolution within a
given population. For example, in a district
that had been hyperendemic at baseline for
trachoma, soil-transmitted helminths, and
lymphatic filariasis but in which interven-
tions had already been in progress for a
number of years, the platform would be
capable of accurately detecting reductions
in ocular C. trachomatis infection, whilst
simultaneously measuring the prevalence
of soil-transmitted helminth infection and
monitoring for post-elimination re-emer-
gence of lymphatic filariasis. Since diseases
of potential interest will vary from one
population to the next, a modular format
would provide opportunities to swap diag-
nostic capacity for particular infections in
and out of the platform according to global,
regional, or local priority. For example, in
onchocerciasis-endemic areas, the capacity
to test for loaiasis at the same time as
measuring the prevalence of O. volvulus
infection would benefit programmes [15].
Equally, the platform should be adapt-
able for the assessment of the community
prevalence of HIV infection, malaria
parasitaemia or anti-malaria antibody,
and/or seroprevalence of antibodies to
measles, rubella, or hepatitis B surface
antigen following vaccination campaigns.
Our vision can be conceptualised as the
delivery of two linked components: a
hardware module, on which samples will
be processed, and various elements of
software, including both the assays them-
selves and the algorithms to guide their use
in the field. To ensure that any new
technologies are ready for both registra-
tion and end use, field personnel, pro-
gramme managers, regulatory agencies,
ministries of health, and other key stake-
holders should be involved in platform
development and evaluation.
In addition to the potential savings to
existing vertical control programmes that
would become possible through integration
of diagnostic tools, this approach has
several other potential advantages.
First, it makes conducting surveys to
rule out specific diseases easier and more
cost-effective. This can occasionally yield
surprising results. In Burundi in 2007,
examination for trachoma was included
alongside fieldwork conducted nationally
to estimate the prevalences of schistosomi-
asis and soil-transmitted helminths, in
order to confirm the long-held belief that
Burundi was trachoma-free. Active tra-
choma was found in children throughout
the country, and trachoma control activ-
ities including azithromycin MDA com-
menced in 2011 in three districts.
Second, proof-of-concept of an integrat-
ed diagnostics platform could facilitate
Table 3. Immediate research priorities.
Disease Research Goal
Feasibility (0–10a: 0,
Impossible; 10, Inevitable)
Impact if Achieved
(0–10a: 0, None; 10, Massive)
Lymphatic filariasis Development of antigen tests to usable/reliable format 9 8 if #USD 0.50
Development and validation of tests (e.g., IgG4-subclass
antibody detection tests using recombinant Bm14, BmR1,
WbSXP, and W. bancrofti-specific antigens [20] or PCR-based
detection of parasite DNA in homogenised mosquitoes [21])
useful for post-elimination surveillance, with accompanying
standardised survey methodologies
9 8 if #USD 0.50
Trachoma Development of a test for ocular C. trachomatis infection
[22] able to maintain specificity at high temperatures and
low humidity [23]
9 8 if #USD 0.50
Development of eye/nose swab-, saliva-, or blood-based anti-C.
trachomatis antibody test and exploration of the impact of
successful trachoma control on antibody profiles in endemic
populations
3 5
Development and validation of a school-based survey protocol
(need threshold minimum school attendance)
7 8
Schistosomiasis Development of antigen [24] or antibody [25] isotype
combination(s) useful in high and low transmission intensity
environments, able to distinguish current from past infection
8 9
Development of antigen or antibody isotype combination(s)
to distinguish between different species
8 4
Development of serum markers of morbidity 6 8
Soil-transmitted
helminthiases
Development of reliable blood- or urine-based assays for
detection of current infection
4 9
Development of serum markers of morbidity 6 8
Onchocerciasis Development of a quantitative antigen test for use in endemic
areas in Africa and validation of Ov16 antibody test for
demonstrating interruption of transmission in Africa
5 8
Development of a test for loaiasis 5 9
aDetermined by expert consensus.
doi:10.1371/journal.pntd.0001746.t003
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programme planning for other infections
for which control strategies are in the early
stages of development. An October 2009
WHO expert consultation discussed recent
work piloting taeniasis elimination in Peru
and possible MDA approaches for food-
borne trematode infections. These diseases
may have global control initiatives devel-
oped in the foreseeable future.
Third, establishing capacity for reliable
diagnosis of what have hitherto been the
most neglected diseases could catalyse a
frame-shift in the global health commu-
nity’s vision of developing world laborato-
ry science. A diagnostics platform that
could be configured to generate commu-
nity- or individual-level data for any of the
infections already mentioned as well as
perform tests for (for example) sexually
transmitted infections, human African
trypanosomiasis, or leishmaniasis would
represent a game-changing advance in the
fight against infectious diseases.
World Health Assembly Resolution
60.29 on Health Technologies recognizes
that medical devices are indispensable
tools for prevention, diagnosis, treatment,
and rehabilitation in health care [16]. It is
widely accepted that the availability of,
and access to, appropriate and affordable
health technologies in low- and middle-
income countries remain inadequate. In
2010, WHO held the first Global Forum
on Medical Devices [17], which featured
selected technological innovations that
could improve global health. The innova-
tors identified financing, manufacturing
partners, and distribution channels as their
top three challenges in getting their
technologies into resource-limited settings.
WHO undertook to continue to interact
with industry, funding agencies, academia,
and international organizations to raise
awareness of the need to design, produce,
and commercialize innovative, accessible,
and robust technologies which address the
needs of health systems particularly in low-
resource settings. The development, eval-
uation, and deployment of an integrated
platform to monitor progress towards
NTD elimination would be consistent with
this WHO vision.
Supporting Information
Table S1 Performance against the AS-
SURED criteria [11] of existing diagnostic
tools for the neglected tropical diseases
employing mass drug administration.
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